ABUS Stock — Arbutus Biopharma Corp

Arbutus Biopharma Corp (ABUS)

Updated October 16, 2026.

ABUS is a Stock. Total return is -40.1% over the past 15.9 years, 782.2 points behind SPY at 742.1%.

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company developing novel therapeutics for infectious disease, with a primary focus on chronic Hepatitis B treatments including Imdusiran, an RNAi therapeutic in phase 2a trials, and AB-101, an oral PD-L1 inhibitor in early-stage clinical trials. The company does not currently have an established distribution schedule. Arbutus appeals primarily to investors with higher risk tolerance who are interested in early-stage biotech development rather than current income generation.

ABUS performance versus SPY

Price and return data through 2026-10-16.

Total return is -40.1% over the past 15.9 years, 782.2 points behind SPY at 742.1%. Over the past year its total return — price change plus distributions reinvested — is -6.4%. Its deepest 1-year drawdown was 25.9%.

ABUS key facts

Asset type

Stock

Asset class

Equity

Inception date

11/15/2010

Distribution frequency

None

Last close

$4.22 (as of 2026-10-16)

Market cap

$646,824,328

Average volume

4541643.0

Beta

0.762

Payout ratio

0.0%

P/E ratio

5.34

Forward P/E

10.2459

EPS

$0.79

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ABUS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 25.9%.

Who may consider ABUS — and who may not

It is a weaker fit for investors who need monthly cash flow (ABUS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ABUS

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions